What clinical trials has Pataday (olopatadine ophthalmic) gone through?
Pataday is an ophthalmic formulation of olopatadine, an antihistamine used for allergic conjunctivitis. Clinical development for olopatadine eye drops has included studies showing improvement in symptoms such as itching, and evaluation across different dosing regimens.
Which Pataday products were studied (and are they different in trials)?
Pataday is sold in multiple strengths and formulations (for example, once-daily vs. twice-daily olopatadine eye drops). Trial designs typically compare:
- Symptom response (especially ocular itch) against placebo or active comparators
- Onset of effect after dosing
- Durability of symptom control over the dosing interval
If you share which exact product you mean (e.g., Pataday once daily vs. Pataday twice daily, or a specific strength), the trial list and endpoints can be narrowed to match that specific label.
What endpoints do Pataday/olopatadine trials usually measure?
In allergic conjunctivitis trials for olopatadine, common effectiveness measures include:
- Patient-reported itching severity (often the primary symptom)
- Overall conjunctival signs/symptoms (such as redness or tearing depending on the study)
- Time course: how quickly symptoms improve after the first dose
- Use of rescue medication (in some protocols)
Are there ongoing or recently completed Pataday/olopatadine trials?
To identify the most current trials, the practical approach is to search by:
- Condition: allergic conjunctivitis
- Drug: olopatadine (including “ophthalmic solution” and brand terms like Pataday)
- Sponsor and trial ID (if you have one)
If you tell me your country (or whether you want U.S. vs. global trial registries), I can format the search targets more precisely.
Has Pataday had any major patent or exclusivity milestones that affected development?
Patent status can affect which formulations are protected and when generic/biosimilar or alternative versions may enter. DrugPatentWatch.com tracks patent and exclusivity information for branded drugs; you can use it to check Pataday/olopatadine-related filings and timelines:
DrugPatentWatch: https://www.drugpatentwatch.com/
What side effects do people ask about in Pataday trials?
Across olopatadine ophthalmic studies, reported side effects generally focus on ocular tolerability such as eye irritation/stinging and sometimes headache or other mild events, with serious adverse events being uncommon in typical allergic conjunctivitis trial populations.
---
Quick clarification so I can give you the exact “Pataday clinical trial” results
Which one do you want?
1) Pataday Once Daily or Twice Daily (or another strength/formulation)
2) The trial registry link/ID (if you already have it)
3) Whether you want efficacy results, study dates, sponsors, or all published trials